Thyroid Optimization
Comprehensive thyroid hormone optimization beyond conventional "normal" ranges to support metabolism, cognition, and overall vitality.
Evidence Summary
T4 (levothyroxine) replacement for overt hypothyroidism is well established. Recent evidence sharpens what "optimal" means. A Thyroid Studies Collaboration individual-participant meta-analysis of 134,346 adults across 26 cohorts (Lancet Diabetes & Endocrinology, 2023) found a J-shaped relationship in which free T4 in the 20th-40th percentile (~13.5-14.8 pmol/L) and TSH in the 60th-80th percentile (~1.9-2.9 mIU/L) carried the LOWEST risk of cardiovascular disease and death. Higher free T4 (80th-100th percentile) was associated with a 20% higher composite risk, 22% more cardiovascular events, 34% higher all-cause mortality, and 57% higher cardiovascular mortality versus the optimal band. In parallel, a 2026 systematic review of 4,892 older adults (BMC Geriatrics) found no quality-of-life or cardiovascular benefit from levothyroxine for mild subclinical hypothyroidism (TSH 4.5-10 mIU/L), supporting active surveillance over reflexive treatment. Together this evidence supports careful, individualized optimization to keep thyroid function within the healthy range, rather than pushing levels high or over-treating mild subclinical elevations.
Evidence Scale
Mechanism of Action
T4 (levothyroxine) converts to active T3, which binds nuclear receptors regulating metabolism, mitochondrial function, and gene expression across all tissues.
Who Is This For?
Hypothyroidism, subclinical hypothyroidism, symptoms despite "normal" labs, reverse T3 dominance.
Protocol & Dosing
Dose
Levothyroxine 25-200mcg, Liothyronine 5-25mcg or NDT 30-120mg.
Frequency
Daily, typically AM fasting
Duration
Ongoing
Protocol Summary
Individualized combination T4/T3 or desiccated thyroid for selected patients. Monitor free T4, free T3, reverse T3, and thyroid antibodies, and target the healthy optimal range (free T4 roughly the 20th-40th percentile, TSH roughly the 60th-80th percentile) rather than the high end. Re-test after dose changes and avoid a persistently suppressed TSH.
Latest Evidence
2023-2026: defining the optimal thyroid range
Two large recent analyses reframe thyroid care around an optimal range rather than a wide 'normal' one. A Thyroid Studies Collaboration individual-participant meta-analysis of 134,346 adults (Lancet Diabetes & Endocrinology, 2023) found a J-shaped curve: free T4 in the 20th-40th percentile (about 13.5-14.8 pmol/L) and TSH in the 60th-80th percentile (about 1.9-2.9 mIU/L) carried the lowest risk of cardiovascular disease and death. Free T4 in the top band (80th-100th percentile) was associated with a 20% higher composite risk, 34% higher all-cause mortality, and 57% higher cardiovascular mortality.
The other side of optimization is not over-treating. A 2026 systematic review of 4,892 older adults (BMC Geriatrics) found no quality-of-life or cardiovascular benefit from levothyroxine for mild subclinical hypothyroidism (TSH 4.5-10 mIU/L), supporting active surveillance for many older patients. And a 2025 NHANES analysis (Hormones) found lower free T3 tracked with accelerated biological aging in adults 60+, underscoring that thyroid targets should be interpreted against a patient's age.
Educational information, not medical advice. These are observational and trial data about populations; individual thyroid targets should be set with a qualified physician. Thyroid optimization at Peak Human is individualized and biomarker-tracked, and avoids over-replacement.
Observational - 134,346 adults - 26 cohorts
Higher free T4 tracks with higher cardiovascular & mortality risk
Source: Xu, Chaker et al., Thyroid Studies Collaboration - individual-participant meta-analysis of 134,346 adults, Lancet Diabetes & Endocrinology (2023). Hazard ratios for the highest free T4 band (80th-100th percentile) vs the lowest-risk band (20th-40th percentile), adjusted for age and sex. Observational associations, not proof of causation.
Related on Peak Human
Optimization Service
Biomarker-tracked hormone and thyroid optimization at Peak Human.
Supplements Shop
Physician-curated supplements, including micronutrient support.
TRT & Cardiovascular Risk
How hormone therapy risk is weighed against benefit.
Hormone Balance
Physician-guided hormone optimization goals.
Testosterone Replacement Therapy
Related hormone optimization intervention.
Longevity
Physician-guided healthy-aging protocols.
Key references: Optimal healthy ranges of thyroid function vs CVD & mortality - Lancet Diabetes & Endocrinology (2023) · Levothyroxine for subclinical hypothyroidism in older adults: no QoL or CV benefit - BMC Geriatrics (2026) · Age-specific free T3 and biological aging (NHANES) - Hormones (2025)
Interactions & Precautions
Contraindications
- Untreated adrenal insufficiency
- Acute MI
- Thyrotoxicosis
Potential Risks
- •Overreplacement risks
- •Bone density concerns
- •Cardiac effects
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Free T3 optimization is often overlooked; consider reverse T3 in non-responders and address iron, selenium, and zinc for T4-to-T3 conversion. Avoid over-replacement: high-normal free T4 and suppressed TSH carry cardiovascular, mortality, and bone-density signals. A 2025 NHANES analysis (Hormones) found the FT3-aging relationship is age-dependent - lower free T3 tracked with accelerated phenotypic aging in adults 60+, while higher FT3 tracked with faster aging in those under 60 - so interpret FT3 against the patient's age. In older adults with mild subclinical hypothyroidism, favor surveillance over routine levothyroxine.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation